Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Study compares survival outcomes in rural and urban cancer patients enrolled in clinical trials

When enrolled in a cancer clinical trial, the differences in survival rates between rural and urban patients are significantly reduced, SWOG study results show.

17 Aug 2018

Hospitals battle for control over fast-growing heart-valve procedure

When Medicare in 2011 agreed to pay for a revolutionary procedure to replace leaky heart valves by snaking a synthetic replacement up through blood vessels, the goal was to offer relief to the tens of thousands of patients too frail to endure open-heart surgery, the gold standard.

17 Aug 2018

University Hospitals Seidman Cancer Center launches new CAR-T therapy trial

University Hospitals Seidman Cancer Center launched a new clinical trial for CAR-T, joining a select group of hospitals offering the therapy and a smaller group of hospitals manufacturing the CAR-T cells.

14 Aug 2018

FDA approves drug for rare, hard-to-treat types of non-Hodgkin lymphoma

The U.S. Food and Drug Administration today approved Poteligeo (mogamulizumab-kpkc) injection for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy.

8 Aug 2018

Research uncovers new approach for expanding stem cells from umbilical cord blood

Researchers from the Stowers Institute for Medical Research and collaborators have identified a way to expand blood-forming, adult stem cells from human umbilical cord blood.

3 Aug 2018

Rutgers researcher receives $100,000 grant to explore T-cell acute lymphoblastic leukemia

A one-year, $100,000 grant awarded to Rutgers Cancer Institute of New Jersey resident researcher Daniel Herranz Benito, PhD, will support exploration into an aggressive blood cancer that impacts both children and adults – T-cell acute lymphoblastic leukemia.

2 Aug 2018

Beckman Coulter introduces expanded range of clinical flow cytometry solutions at AACC 2018

Beckman Coulter continues to expand portfolio of clinical flow cytometry solutions with its latest innovations.

From Beckman Coulter Life Sciences - Flow Cytometry 30 Jul 2018

Janssen’s Darzalex receives positive CHMP opinion for treating multiple myeloma patients

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended broadening the existing marketing authorization for Darzalex® for use as frontline therapy.

28 Jul 2018

CNDA approves KEYTRUDA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.

26 Jul 2018

Newly identified target may lead to discovery of treatments for chronic inflammatory diseases

Inflammation is part of the body's natural healing process. But when it becomes chronic, inflammation can lead to cancer, Alzheimer's disease and other conditions.

26 Jul 2018

Researchers find compounds that may pave way for new drugs against diabetes, obesity

A new study reveals that several drugs for treating hematological cancers are less effective than expected in inhibiting a special enzyme.

26 Jul 2018

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.

25 Jul 2018

'Hijacked' cell response to stress reveals potential therapeutic targets for leukemia

A signaling pathway that helps promote normal cell growth worsens a form of leukemia by taking control of another pathway better known for protecting cells from biological stress, a new study shows.

24 Jul 2018

AbbVie submits supplemental NDA to FDA for venetoclax to treat acute myeloid leukemia

AbbVie, a research-based global biopharmaceutical company, today announced it submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for venetoclax in combination with a hypomethylating agent or in combination with low-dose cytarabine for the treatment of newly diagnosed patients with acute myeloid leukemia who are ineligible for intensive chemotherapy.

20 Jul 2018

Scientists identify melanoma biomarkers that could help tailor immunotherapy treatments

Scientists at Dana-Farber/Brigham and Women's Cancer Center have identified biomarkers in melanoma that could help tailor immunotherapy treatments to maximize the benefits for patients while reducing the likelihood of severe side effects.

19 Jul 2018

Homogenous BTK occupancy assay used in tirabrutinib clinical studies

In a new SLAS Discovery article, Helen Yu and a team of researchers at Gilead Sciences, Inc. present a time-resolved fluorescence resonance energy transfer-based Bruton's tyrosine kinase occupancy assay that can measure target engagement in peripheral blood mononuclear cells and in lymph-node and bone-marrow samples.

17 Jul 2018

Staggering prices slow insurers’ coverage of CAR-T cancer therapy

Patients whose blood cancers have failed to respond to repeated rounds of chemotherapy may be candidates for a new type of gene therapy that could send their cancers into remission for years.

17 Jul 2018

Scientists discover new way to predict healthy individuals at risk of developing AML

An international team of leukemia scientists has discovered how to predict healthy individuals at risk of developing acute myeloid leukemia, an aggressive and often deadly blood cancer.

10 Jul 2018

Altitude sickness drug may offer significant gains for patients with glioblastoma

A drug used to treat altitude sickness -- as well as glaucoma, epilepsy, heart failure and seizures -- may also offer significant gains for patients with a fast-growing brain tumor known as glioblastoma, according to a study published July 4, 2018, in the journal Science Translational Medicine.

10 Jul 2018

CTI BioPharma announces Phase III results of PIXUVRI combined with rituximab in aggressive B-cell NHL patients

CTI BioPharma Corp. and Servier today announced that the pivotal Phase III study evaluating PIXUVRI® combined with rituximab in comparison to gemcitabine combined with rituximab in patients with aggressive B-cell non-Hodgkin lymphoma did not meet its primary endpoint of improvement of progression-free survival

9 Jul 2018

Lymphoma News and Research

Further Reading

Study compares survival outcomes in rural and urban cancer patients enrolled in clinical trials

Hospitals battle for control over fast-growing heart-valve procedure

University Hospitals Seidman Cancer Center launches new CAR-T therapy trial

FDA approves drug for rare, hard-to-treat types of non-Hodgkin lymphoma

Research uncovers new approach for expanding stem cells from umbilical cord blood

Rutgers researcher receives $100,000 grant to explore T-cell acute lymphoblastic leukemia

Beckman Coulter introduces expanded range of clinical flow cytometry solutions at AACC 2018

Janssen’s Darzalex receives positive CHMP opinion for treating multiple myeloma patients

CNDA approves KEYTRUDA for treatment of advanced melanoma

Newly identified target may lead to discovery of treatments for chronic inflammatory diseases

Researchers find compounds that may pave way for new drugs against diabetes, obesity

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

'Hijacked' cell response to stress reveals potential therapeutic targets for leukemia

AbbVie submits supplemental NDA to FDA for venetoclax to treat acute myeloid leukemia

Scientists identify melanoma biomarkers that could help tailor immunotherapy treatments

Homogenous BTK occupancy assay used in tirabrutinib clinical studies

Staggering prices slow insurers’ coverage of CAR-T cancer therapy

Scientists discover new way to predict healthy individuals at risk of developing AML

Altitude sickness drug may offer significant gains for patients with glioblastoma

CTI BioPharma announces Phase III results of PIXUVRI combined with rituximab in aggressive B-cell NHL patients

Everything you should know about lymphoma eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News